Entrust delivery system launched in the United States


Medtronic announced the launch of its Entrust delivery system in the United States on 5 August 2015. The new Entrust delivery system enables physicians to place Medtronic’s EverFlex self-expanding peripheral stent, while maintaining a low profile and providing the ease of a one-handed device.

“The Entrust delivery system allows me to confidently deliver the EverFlex stent with control and ease, ensuring precise placement of the stent even in difficult, complex or hard to reach lesions,” said George Meier, chief of Vascular Surgery, University of Cincinnati Medical Center.

The Entrust delivery system deploys the EverFlex stent to re-open stenotic regions of the superficial femoral and proximal popliteal arteries.


“The Entrust delivery system is a great example of how industry and physicians can partner to deliver game-changing technology,” said Luke Marone, chief Cardiovascular Surgery, UPMC Passavant Hospital, director of Peripheral Intervention UPMC HVI. “The low-profile, long catheter option, and one-handed, triaxial delivery system put the Entrust delivery system in a class of its own when it comes to peripheral vascular stents.”

According to Medtronic, the Entrust delivery system provides control and precision with its 5F triaxial delivery system and its distinctive combination of features, including 0.035” guidewire compatibility, longer catheter lengths, and a broad stent matrix. The Entrust delivery system uses the EverFlex stent, which has been clinically proven to be safe and effective in treating long, complex and highly calcified lesions.

“Based on physician feedback and procedural observation, we developed an easy to use one-handed delivery system to increase the stent delivery options in our portfolio,” said Brian Verrier, vice president and general manager of Peripheral Vascular, a business in Medtronic’s Aortic and Peripheral Vascular division. “Both the Entrust delivery system and the EverFlex stent with the pin-pull delivery system provide enhanced choice and treatment solutions for peripheral arterial disease.”